You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In a research note, the investment house cited concerns about Cepheid's high price-to-sale ratio but said that the firm's installed base is expected to grow 27 percent year over year in 2011.
The investment firm lowered EPS estimates for Illumina on an expected shift to the MiSeq platform from the HiSeq system, but said that in a short amount of time Illumina's desktop sequencer would overtake Ion Torrent's PGM as the market leader.
The bank raised its price target on Cepheid's stock from $33 to $38 and upped its revenues and EPS estimates for 2012.
The investment firm lowered revenue estimates and the share-price target for Nanosphere following the FDA's denial of the company's Plavix metabolism test.
Jefferies also increased the firm's stock price target to $20 from $15.50.
Shares of the company climbed as much as 13 percent, and in an analyst note, R.W. Baird said incoming CEO Frank Witney could return Affymetrix to top-line growth.
Macquarie cited competition and potential budget cuts in downgrading Qiagen's shares, lowering its revenue and EPS estimates, and pushing down its target share price.
Analysts revised EPS and revenue estimates as well as target prices following earnings releases on Tuesday by Illumina, Life Technologies, Waters, and Becton Dickinson.
Oppenheimer increased its price target and revenue estimates on Complete Genomics, while Jefferies raised its EPS and price target for Danaher.
An analyst for the investment firm gave PacBio a "Market Perform" rating and Complete Genomics an "Outperform" rating.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.